A year in review: Summit Therapeutics Inc (SMMT)’s performance in the last year

While Summit Therapeutics Inc has overperformed by 1.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SMMT rose by 140.29%, with highs and lows ranging from $36.91 to $6.78, whereas the simple moving average fell by -3.08% in the last 200 days.

On June 11, 2025, Leerink Partners started tracking Summit Therapeutics Inc (NASDAQ: SMMT) recommending Underperform. A report published by Citigroup on March 26, 2025, Upgraded its rating to ‘Buy’ for SMMT. Evercore ISI Initiated an Outperform rating on March 12, 2025, and assigned a price target of $30. Goldman initiated its ‘Buy’ rating for SMMT, as published in its report on February 28, 2025. Truist’s report from January 08, 2025 suggests a price prediction of $35 for SMMT shares, giving the stock a ‘Buy’ rating. Wells Fargo also rated the stock as ‘Overweight’.

Analysis of Summit Therapeutics Inc (SMMT)

Summit Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -123.93% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.63, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

The average volume for any stock is also a very valuable indicator of volatility, and SMMT has an average volume of 4.69M. On a monthly basis, the volatility of the stock is set at 9.73%, whereas on a weekly basis, it is put at 1.53%, with a gain of 2.96% over the past seven days. Furthermore, long-term investors anticipate a median target price of $34.10, showing growth from the present price of $20.16, which can serve as yet another indication of whether SMMT is worth investing in or should be passed over.

How Do You Analyze Summit Therapeutics Inc Shares?

In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 84.99%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 13.17% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

SMMT shares are owned by institutional investors to the tune of 13.17% at present.

Hot this week

Is ProFrac Holding Corp (ACDC) worth investing in despite its undervalued state?

While ProFrac Holding Corp has underperformed by -0.24%, investors...

Are Companhia Siderurgica Nacional ADR (SID) shares a good deal now?

While Companhia Siderurgica Nacional ADR has underperformed by -2.08%,...

Adaptimmune Therapeutics Plc ADR (ADAP) requires closer examination

While Adaptimmune Therapeutics Plc ADR has overperformed by 4.70%,...

uniQure N.V (QURE) shows promising results

While uniQure N.V has overperformed by 1.94%, investors are...

What was Newell Brands Inc (NWL)’s performance in the last session?

While Newell Brands Inc has underperformed by -0.95%, investors...

Topics

Is ProFrac Holding Corp (ACDC) worth investing in despite its undervalued state?

While ProFrac Holding Corp has underperformed by -0.24%, investors...

Are Companhia Siderurgica Nacional ADR (SID) shares a good deal now?

While Companhia Siderurgica Nacional ADR has underperformed by -2.08%,...

Adaptimmune Therapeutics Plc ADR (ADAP) requires closer examination

While Adaptimmune Therapeutics Plc ADR has overperformed by 4.70%,...

uniQure N.V (QURE) shows promising results

While uniQure N.V has overperformed by 1.94%, investors are...

What was Newell Brands Inc (NWL)’s performance in the last session?

While Newell Brands Inc has underperformed by -0.95%, investors...

Is Spire Global Inc (SPIR) a good investment opportunity?

While Spire Global Inc has overperformed by 2.37%, investors...

Aclaris Therapeutics Inc (ACRS) presents a great opportunity, but the stock is slightly overvalued

While Aclaris Therapeutics Inc has overperformed by 9.35%, investors...

Is it possible to buy LiveOne Inc(LVO) shares at a good price now?

While LiveOne Inc has underperformed by -2.29%, investors are...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.